BeStock  
Stocks › Biotechnology › CYTK

Cytokinetics CYTK

US equityMarket cap rank #1720Biotechnology
$50.78 −$0.68 (-1.32%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $52.48 +3.35%
Open$51.27
Prev close$51.46
Day range$50.60 – $53.45
Volume1.43M
Market cap$7.07B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$47.56M+2,356.5% YoY
Operating profit-$167.09M-0.2% YoY
Net profit-$190.07M+37.9% YoY
Diluted EPS-$1.37+46.3% YoY
Free cash flow-$124.72M-6.7% YoY
Operating cash flow-$124.02M

Revenue, last 8 quarters

$16.9MDec '24$1.6MMar '25$66.8MJun '25$1.9MSep '25$17.8MDec '25$19.4MMar '26$28.6MJun '26$47.6MSep '26

Net profit, last 8 quarters

$-150.0MDec '24$-161.4MMar '25$-134.4MJun '25$-306.2MSep '25$-183.0MDec '25$-206.0MMar '26$-198.8MJun '26$-190.1MSep '26

Diluted EPS by quarter

-1.26Dec '24-1.36Mar '25-1.12Jun '25-2.55Sep '25-1.50Dec '25-1.67Mar '26-1.50Jun '26-1.37Sep '26

Free cash flow by quarter

$-66.9MDec '24$-137.3MMar '25$-132.4MJun '25$-116.9MSep '25$-148.3MDec '25$-151.4MMar '26$-164.2MJun '26$-124.7MSep '26

Annual revenue

$55.8MFY20$70.4MFY21$94.6MFY22$7.5MFY23$18.5MFY24$88.0MFY25

Profitability & balance sheet

Gross margin95.3%
Operating margin-625.2%
Net margin-686.6%
Return on assets-47.7%
Current ratio3.36
Liabilities / assets117.6%
Cash & investments$1.13B
Total debt$1.25B
Net cash (debt)-$121.15M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $47.56M $28.62M $19.36M $88.04M $17.76M
Total Operating Revenue $47.56M $28.62M $19.36M $88.04M $17.76M
Cost of Revenue $2.22M $5.59M $2.55M – –
Gross Profit $45.34M $23.03M $16.80M – –
Operating Expense $212.43M $202.20M $200.42M $700.30M $202.05M
Selling and Admin Expenses $113.14M $104.40M $104.90M $284.27M $91.72M
-General & Admin Expense $113.14M – – $284.27M $91.72M
Research & Development $99.29M $97.81M $95.53M $416.03M $110.33M
Operating Profit -$167.09M -$179.17M -$183.62M -$612.26M -$178.37M
Net Non-Operating Interest Income (Expense) -$22.58M -$20.89M -$22.31M -$55.45M -$18.87M
Non-Operating Interest Income $15.90M $13.94M $11.02M $48.42M $11.47M
Non-Operating Interest Expense $38.48M $34.83M $33.34M $103.87M $30.34M
Other Income (Expense) -$400,000.00 $1.30M -$100,000.00 -$117.25M $14.20M
Gain on Sale of Security -$600,000.00 -$1.10M $1.50M $4.20M $900,000.00
Special Income (Charges) $0.00 – – -$121.25M $0.00
Other Non-Operating Income (Expenses) $200,000.00 $2.40M -$1.60M -$200,000.00 $13.30M
Pretax Profit -$190.07M -$198.76M -$206.03M -$784.96M -$183.03M
Net Profit -$190.07M -$198.76M -$206.03M -$784.96M -$183.03M
Profit from Continuing Operations -$190.07M -$198.76M -$206.03M -$784.96M -$183.03M
Net Income to Parent Company -$190.07M -$198.76M -$206.03M -$784.96M -$183.03M
Net Income to Common Stockholders -$190.07M -$198.76M -$206.03M -$784.96M -$183.03M
Basic EPS -$1.37 -$1.50 -$1.67 -$6.54 -$1.50
Diluted EPS -$1.37 -$1.50 -$1.67 -$6.54 -$1.50
-Less:Other Special Charges – – – $121.25M $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.82B $1.92B $1.27B $1.42B $1.42B
Total Current Assets $1.19B $1.21B $839.47M $916.98M $916.98M
Cash and Cash Equivalents & Short-Term Investments $1.13B $1.17B $818.55M $882.22M $882.22M
-Cash and Cash Equivalents $203.43M $255.27M $129.84M $122.52M $122.52M
-Short Term Investments $926.59M $910.42M $688.71M $759.70M $759.70M
Receivables $33.89M $24.43M $6.83M $17.76M $17.76M
-Accounts Receivable $33.89M $24.43M $6.83M $17.76M $17.76M
Inventory $807,000.00 $380,000.00 $154,000.00 – –
Other Current Assets $22.43M $17.99M $13.93M $16.99M $16.99M
Total Non-Current Assets $637.63M $716.06M $434.01M $507.56M $507.56M
Net PPE $147.69M $151.81M $156.98M $155.17M $155.17M
-Gross PPE $147.69M $151.81M $156.98M $202.47M $202.47M
Investments and Advances $453.63M $538.32M $254.72M $335.05M $335.05M
-Available for Sale Securities $453.63M $538.32M $254.72M $335.05M $335.05M
Other Non-Current Assets $36.31M $25.94M $22.31M $17.34M $17.34M
Total Liabilities $2.15B $2.10B $2.10B $2.08B $2.08B
Total Current Liabilities $353.42M $181.43M $199.19M $202.45M $202.45M
Payables $25.96M $20.51M $24.71M $22.34M $22.34M
-Accounts Payable $25.96M $20.51M $24.71M $22.34M $22.34M
Current Accrued Expenses $43.10M $42.52M $41.51M $38.13M $38.13M
Short-Term Debt and Capital Lease Obligation $195.79M $48.40M $65.77M $60.29M $60.29M
-Current Debt $174.40M $27.36M $44.81M $41.18M $41.18M
-Current Capital Lease Obligation $21.39M $21.04M $20.96M $19.11M $19.11M
Current Deferred Liabilities $1.65M $1.65M $1.65M $1.61M $1.61M
Other Current Liabilities $39.14M $34.00M $38.19M $34.93M $34.93M
Total Non-Current Liabilities $1.79B $1.92B $1.90B $1.88B $1.88B
Long Term Debt and Capital Lease Obligation $1.08B $1.22B $1.22B $1.22B $1.22B
-Long Term Debt $977.10M $1.12B $1.12B $1.12B $1.12B
-Long Term Capital Lease Obligation $99.67M $102.43M $105.24M $107.97M $107.97M
Other Non-Current Liabilities $715.76M $694.45M $677.91M $657.76M $657.76M
Total Equity -$321.17M -$173.49M -$826.57M -$659.63M -$659.63M
Stockholders' Equity -$321.17M -$173.49M -$826.57M -$659.63M -$659.63M
Capital Stock $139,000.00 $138,000.00 $124,000.00 $123,000.00 $123,000.00
-Common Stock $139,000.00 $138,000.00 $124,000.00 $123,000.00 $123,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $3.77B $3.72B $2.87B $2.83B $2.83B
Retained Earnings -$4.08B -$3.89B -$3.69B -$3.49B -$3.49B
Gains/Losses Not Affecting Retained Earnings -$8.39M -$3.83M -$1.61M $630,000.00 $630,000.00
-Accumulated Depreciation – – – -$47.30M -$47.30M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$124.02M -$159.84M -$145.46M -$510.01M -$142.65M
Net cash flow from continuing operations -$124.02M -$159.84M -$145.46M -$510.01M -$142.65M
Net Income from Continuing Operations -$190.07M -$198.76M -$206.03M -$784.96M -$183.03M
Gain/Loss from Continuing Operations $537,000.00 $1.04M -$1.56M -$4.23M -$908,000.00
Depreciation & Depletion & Amortization $3.65M $3.63M $3.38M $10.13M $2.86M
Other Non-Cash Items $29.92M $23.78M $28.58M $192.39M $9.77M
Change in Working Capital -$2.78M -$25.24M -$219,000.00 -$35.63M -$1.85M
-Change in Receivables -$9.46M -$17.61M $10.94M -$1.11M -$15.96M
-Change in Inventory -$9.29M -$2.26M -$3.57M – –
-Change in Prepaid Assets -$5.11M -$4.84M $2.06M -$2.93M -$4.20M
-Change in Payables and Accrued Expense $30.27M $5.28M -$4.69M $36.27M $26.06M
-Change in Other Current Liabilities -$9.19M -$5.81M -$4.99M -$17.09M -$7.75M
-Change In Other Working Capital $0.00 $0.00 $41,000.00 -$50.76M $0.00
Net cash flow from investing $67.93M -$507.00M $145.49M $16.67M -$71.19M
Net Cash Flow from Continuing Investing Activities $67.93M -$507.00M $145.49M $16.67M -$71.19M
Net PPE Purchase and Sale -$700,000.00 -$4.33M -$5.93M -$24.81M -$5.64M
Net Investment Purchase and Sale $68.63M -$502.66M $151.42M $41.47M -$65.55M
Financing Cash Flow $4.80M $792.86M $7.77M $524.46M $110.71M
Net Cash Flow from Continuing Financing Activities $4.80M $792.86M $7.77M $524.46M $110.71M
Net Issuance Payments Of Debt -$5.41M -$3.59M -$2.74M $315.95M -$2.72M
Net Common Stock Issuance -$1,000.00 – – $0.00 $0.00
Proceeds from Stock Option Exercised $12.41M $38.00M $11.35M $35.98M $14.65M
Net Other Financing Charges -$2.20M -$1.70M -$841,000.00 $172.53M $98.78M
Ending Cash Balance $206.53M $258.38M $132.95M $125.63M $125.63M
Net Change in Cash -$51.29M $126.02M $7.81M $31.12M -$103.14M
Beginning Cash Balance $258.38M $132.95M $125.63M $95.23M $228.58M
Effect of Exchange Rate Changes -$559,000.00 -$595,000.00 -$483,000.00 -$715,000.00 $191,000.00
Free Cash Flow -$124.72M -$164.17M -$151.39M -$534.82M -$148.30M

Discussion

No comments yet — be the first to weigh in on CYTK.

Sign in to join the discussion.

Scroll to Top